Ignite Creation Date:
2025-12-25 @ 12:35 AM
Ignite Modification Date:
2026-02-02 @ 12:16 AM
Study NCT ID:
NCT01576367
Status:
COMPLETED
Last Update Posted:
2018-09-11
First Post:
2012-02-17
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
Sponsor:
Novartis Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Cryopyrin-associated periodic syndromes (CAPS) | View |
| None | Familial Cold Autoinflammatory Syndrome (FCAS) | View |
| None | Muckle-Wells Syndrome (MWS) | View |
| None | Neonatal Onset Multisystem Inflammatory Disease (NOMID) | View |
| None | children, systemic autoinflammatory disease | View |
| None | CIAS-1 gene | View |
| None | NALP-3 | View |
| None | NLRP3 | View |
| None | ACZ885 | View |
| None | canakinumab | View |
| None | human monoclonal anti-human interleukin-1 antibody | View |
| None | autosomal dominant | View |
| None | familial autoinflammatory syndrome | View |
| None | childhood immunizations vaccinations | View |